Copyright © Inderes 2011 - present. All rights reserved.

Novo Nordisk

364.70 DKK

-0.46 %

Less than 1K followers

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

-0.46 %
+12.13 %
+17.80 %
-2.93 %
-17.34 %
-39.50 %
-24.61 %
+72.82 %
+29,193.17 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.63T DKK
Turnover
619.61M DKK
Revenue
290.4B
EBIT %
44.19 %
P/E
16.09
Dividend yield-%
3.13 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4/2
2026

Annual report '25

26/3
2026

General meeting '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
An executive at Novo Nordisk told me directly earlier this autumn that getting Kela reimbursement has been “in the works” for a while, but the biggest challenge here is purely the price. If semaglutide were to be reimbursed for the obesity indication, the costs would be massive. ...
12/29/2025, 7:46 PM
by JNivala
89
This hasn’t been posted here yet, but a win for Novo in China. pharmaphorum China delivers a win for Novo Nordisk on semaglutide IP Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which backed the validity of its patent on GLP-1 agonist semaglutide. This...
yesterday
69
Now that the United States has struck Venezuela and there is already speculation about a war between Denmark and the USA, one could assume that Novo, as a Danish company, could at least be a short-term sufferer as the markets begin to reassess Novo’s future cash flows. If the USA...
1/4/2026, 8:59 AM
by Blackparta
28
Similarly, my gut feeling is that the US will undoubtedly reach some kind of deal with Denmark & Greenland, but it won’t be the kind that would cause NATO to fragment internally or lead Denmark into an armed conflict. Regarding the thread’s topic, NOVO will likely bounce back from...
1/5/2026, 12:51 PM
by Jummijammi2
20
Here is an article about Novo stating that next year (well, this year 2026 :D) the company will be in a tight spot, and the piece lists how they have a miserable year behind them, the stock has been sliding, and competitor Lilly has powered past. (if you can even put it that way)...
1/1/2026, 9:28 AM
by Sijoittaja-alokas
19
True, some of the threat has likely already been priced into Danish companies. This is getting a bit speculative, but attacking a NATO founding member would be such a shock to the current world order that the entire Western market would go down with the bathwater. It’s hard to believe...
1/4/2026, 8:39 PM
by Ränta på ränta
17
https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-us-public-affairs-head-leaves-company-memo-shows-2026-01-05/ Novo’s US public affairs head has left to seek greener pastures outside the company. A quick Google search reveals they were a Biden-era individual...
1/5/2026, 6:24 PM
by zyippi
12
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.